{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:57:39Z","timestamp":1784170659513,"version":"3.55.0"},"reference-count":43,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["K142273"],"award-info":[{"award-number":["K142273"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hungarian Society for Endocrinology and Metabolism"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The role of insulin-like growth factor-binding proteins (IGFBPs) in the regulation of carbohydrate metabolism and the development of complications is well established; however, the impact of the glucagon-like peptide-1 receptor agonist semaglutide on IGFBPs has not been previously investigated. We aimed to examine the effects of semaglutide and dipeptidyl peptidase-4 inhibitor sitagliptin therapy on serum levels of IGFBP-1, IGFBP-3, and IGFBP-rp1, and to analyze their associations with anthropometric variables and markers of carbohydrate and lipid metabolism. In this prospective study, we enrolled 34 patients with type 2 diabetes mellitus (T2DM) on metformin monotherapy and 31 age-, sex- and BMI-matched controls. Among the patients, 18 received semaglutide, and 16 were treated with sitagliptin. Anthropometric and laboratory assessments were performed at baseline, 26 and 52 weeks. IGFBP levels were measured using ELISA. Both semaglutide and sitagliptin treatment significantly increased IGFBP-1 levels. IGFBP-3 levels were significantly decreased following sitagliptin therapy. No significant change in IGFBP-rp1 levels was observed with either treatment. Based on multiple regression analysis, the best predictors of IGFBP-1 were insulin and hsCRP, while the best predictor of IGFBP-3 was LDL-C level. Our findings suggest that semaglutide and sitagliptin may exert favorable effects on the GH\/IGF-1 axis, potentially contributing to their beneficial metabolic outcomes in patients with T2DM.<\/jats:p>","DOI":"10.3390\/ijms262110404","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:51:42Z","timestamp":1761526302000},"page":"10404","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Effects of Semaglutide and Sitagliptin on Circulating IGFBP-1, IGFBP-3 and IGFBP-rp1: Results from a One-Year Study in Type 2 Diabetes"],"prefix":"10.3390","volume":"26","author":[{"given":"Eszter","family":"D\u00e1niel","sequence":"first","affiliation":[{"name":"Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary"},{"name":"Doctoral School of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"Sztanek","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ra","family":"Csiha","sequence":"additional","affiliation":[{"name":"Doctoral School of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary"},{"name":"Department of Clinical Basics, Faculty of Pharmacy, University of Debrecen, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0991-8622","authenticated-orcid":false,"given":"Bal\u00e1zs","family":"Ratku","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary"},{"name":"Institute of Health Studies, Faculty of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor","family":"Somodi","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary"},{"name":"Institute of Health Studies, Faculty of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Paragh","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9761-9595","authenticated-orcid":false,"given":"Mariann","family":"Harangi","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary"},{"name":"Institute of Health Studies, Faculty of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5303-3082","authenticated-orcid":false,"given":"Hajnalka","family":"L\u0151rincz","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101882","DOI":"10.1016\/j.jacadv.2025.101882","article-title":"Type 2 Diabetes Mellitus-Related Mortality in the United States, 1999 to 2023","volume":"4","author":"Ahmed","year":"2025","journal-title":"JACC Adv."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10741-020-10005-5","article-title":"Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection","volume":"26","author":"Rankovic","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Sztanek, F., T\u00f3th, L.I., Pet\u0151, A., Herny\u00e1k, M., Di\u00f3szegi, \u00c1., and Harangi, M. (2024). New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes\u2014Beyond and within GLP-1 Receptor Agonists. Biomedicines, 12.","DOI":"10.3390\/biomedicines12061320"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"T\u00f3th, L.I., Hars\u00e1nyi, A., Csiha, S., Moln\u00e1r, \u00c1., L\u0151rincz, H., Nagy, A.C., Paragh, G., Harangi, M., and Sztanek, F. (2025). Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26135951"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.molmet.2018.10.008","article-title":"The insulin like growth factor and binding protein family: Novel therapeutic targets in obesity & diabetes","volume":"19","author":"Haywood","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1210\/er.2001-0033","article-title":"Cellular actions of the insulin-like growth factor binding proteins","volume":"23","author":"Firth","year":"2002","journal-title":"Endocr. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s001250051623","article-title":"Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations","volume":"44","author":"Heald","year":"2001","journal-title":"Diabetologia"},{"key":"ref_10","first-page":"1935","article-title":"Insulin-like growth factor binding protein-I levels are strongly associated with insulin sensitivity and obesity in early pubertal children","volume":"83","author":"Travers","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1530\/EJE-10-0301","article-title":"IGF-binding protein 1 and abdominal obesity in the development of type 2 diabetes in women","volume":"163","author":"Lewitt","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1530\/EJE-09-0852","article-title":"IGF1 and its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men","volume":"162","author":"Yeap","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1203\/pdr.0b013e31802d8a30","article-title":"Insulin-like growth factor binding protein-3 induces insulin resistance in adipocytes in vitro and in rats in vivo","volume":"61","author":"Kim","year":"2007","journal-title":"Pediatr. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"E937","DOI":"10.1152\/ajpendo.00014.2002","article-title":"Impaired glucose homeostasis in insulin-like growth factor-binding protein-3-transgenic mice","volume":"283","author":"Silha","year":"2002","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1868-7083-5-20","article-title":"Evaluation of IGFBP-7 DNA methylation changes and serum protein variation in Swedish subjects with and without type 2 diabetes","volume":"5","author":"Gu","year":"2013","journal-title":"Clin. Epigenetics"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2337\/db05-1627","article-title":"Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1\/MAC25)","volume":"55","author":"Khosravi","year":"2006","journal-title":"Diabetes"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3390\/jcm3041561","article-title":"The Insulin-Like Growth Factor System in Obesity, Insulin Resistance and Type 2 Diabetes Mellitus","volume":"3","author":"Lewitt","year":"2014","journal-title":"J. Clin. Med."},{"key":"ref_18","first-page":"1369","article-title":"Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in noninsulin-dependent diabetes mellitus","volume":"80","author":"Gibson","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kang, H.S., Cho, H.C., Lee, J.H., Oh, G.T., Koo, S.H., Park, B.H., Lee, I.K., Choi, H.S., Song, D.K., and Im, S.S. (2016). Metformin stimulates IGFBP-2 gene expression through PPARalpha in diabetic states. Sci. Rep., 6.","DOI":"10.1038\/srep23665"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Chikata, Y., Iwata, H., Miyosawa, K., Koike, T., Yasuda, H., Funamizu, T., Doi, S., Endo, H., Wada, H., and Naito, R. (2022). Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-09059-2"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.2337\/dc20-0456","article-title":"Mechanisms of Sodium-Glucose Cotransporter 2 Inhibition: Insights from Large-Scale Proteomics","volume":"43","author":"Ferrannini","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12933-023-01916-2","article-title":"Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: An analysis from the CREDENCE trial","volume":"22","author":"Mohebi","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tem.2009.01.002","article-title":"IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: Implications for metabolic homeostasis","volume":"20","author":"Wheatcroft","year":"2009","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Brismar, K., Hilding, A., Ansurudeen, I., Flyvbjerg, A., Frystyk, J., and \u00d6stenson, C.G. (2022). Adiponectin, IGFBP-1 and -2 are independent predictors in forecasting prediabetes and type 2 diabetes. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1092307"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.2337\/db11-1488","article-title":"Insulin-like growth factor axis and risk of type 2 diabetes in women","volume":"61","author":"Rajpathak","year":"2012","journal-title":"Diabetes"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1530\/EJE-22-0034","article-title":"Low IGF1 and high IGFBP1 predict diabetes onset in prediabetic patients","volume":"187","author":"Meyer","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.15252\/embj.201592903","article-title":"IGFBP1 increases \u03b2-cell regeneration by promoting \u03b1- to \u03b2-cell transdifferentiation","volume":"35","author":"Lu","year":"2016","journal-title":"EMBO J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2337\/diacare.25.10.1807","article-title":"Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes","volume":"25","author":"Leinonen","year":"2002","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Varma Shrivastav, S., Bhardwaj, A., Pathak, K.A., and Shrivastav, A. (2020). Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3): Unraveling the Role in Mediating IGF-Independent Effects Within the Cell. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00286"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1210\/jc.2005-0595","article-title":"Insulin-like growth factor binding protein-3 leads to insulin resistance in adipocytes","volume":"90","author":"Chan","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1210\/jc.2017-01273","article-title":"The Association Between IGF-I and IGFBP-3 and Incident Diabetes in an Older Population of Men and Women in the Cardiovascular Health Study","volume":"102","author":"Xue","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Rahman, A., Hammad, M.M., Al Khairi, I., Cherian, P., Al-Sabah, R., Al-Mulla, F., Abu-Farha, M., and Abubaker, J. (2021). Profiling of Insulin-Like Growth Factor Binding Proteins (IGFBPs) in Obesity and Their Association with Ox-LDL and Hs-CRP in Adolescents. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.727004"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Gallwitz, B. (2019). Clinical Use of DPP-4 Inhibitors. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00389"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E654","DOI":"10.1152\/ajpendo.90846.2008","article-title":"Inhibition of adipocyte differentiation by insulin-like growth factor-binding protein-3","volume":"296","author":"Chan","year":"2009","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1210\/en.2011-1444","article-title":"Interaction between IGF binding protein-3 and TGF\u03b2 in the regulation of adipocyte differentiation","volume":"153","author":"Firth","year":"2012","journal-title":"Endocrinology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/EJE-13-1017","article-title":"Cross-sectional and longitudinal relation of IGF1 and IGF-binding protein 3 with lipid metabolism","volume":"171","author":"Eggert","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/01.ATV.0000154486.03017.35","article-title":"Circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 are associated with early carotid atherosclerosis","volume":"25","author":"Kawachi","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Lit, K.K., Zhirenova, Z., and Blocki, A. (2024). Insulin-like growth factor-binding protein 7 (IGFBP7): A microenvironment-dependent regulator of angiogenesis and vascular remodeling. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1421438"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Liu, Y., Wu, M., Ling, J., Cai, L., Zhang, D., Gu, H.F., Wang, H., Zhu, Y., and Lai, M. (2015). Serum IGFBP7 levels associate with insulin resistance and the risk of metabolic syndrome in a Chinese population. Sci. Rep., 5.","DOI":"10.1038\/srep10227"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4085\/1062-6050-43.2.215","article-title":"Issues in outcomes research: An overview of randomization techniques for clinical trials","volume":"43","author":"Kang","year":"2008","journal-title":"J. Athl. Train."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.319.7211.703","article-title":"How to randomise","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/21\/10404\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:59:57Z","timestamp":1761526797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/21\/10404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,26]]},"references-count":43,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["ijms262110404"],"URL":"https:\/\/doi.org\/10.3390\/ijms262110404","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,26]]}}}